The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
webdev2020 年 2 月 19 日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Certara2019 年 12 月 19 日
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…
Certara2019 年 10 月 24 日
Innovative Solutions for Fast-Tracking Drugs for Rare Diseases
This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…
webdev2019 年 8 月 10 日
Evidence and Access Overview
Discover Certara’s holistic approach to market access.
webdev2019 年 5 月 21 日
Advanced Analytics Using RWD Mitigates Risks in AD Drug Development & Reimbursement
This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…
webdev2019 年 5 月 13 日
Trends for Market Access, HEOR, and Real World Evidence
This blog reviews trends for using health economics and outcomes research and real-world evidence to…
Certara2019 年 5 月 10 日
Real World Evidence Marches Forward in Drug Development
The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…
Certara2019 年 3 月 20 日
Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond
Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…
Jieun Choe2018 年 6 月 2 日
